LU77387A1 - - Google Patents

Info

Publication number
LU77387A1
LU77387A1 LU77387A LU77387A LU77387A1 LU 77387 A1 LU77387 A1 LU 77387A1 LU 77387 A LU77387 A LU 77387A LU 77387 A LU77387 A LU 77387A LU 77387 A1 LU77387 A1 LU 77387A1
Authority
LU
Luxembourg
Application number
LU77387A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of LU77387A1 publication Critical patent/LU77387A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
LU77387A 1976-05-24 1977-05-23 LU77387A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL7605526A NL7605526A (nl) 1976-05-24 1976-05-24 Nieuwe tetracyclische derivaten.

Publications (1)

Publication Number Publication Date
LU77387A1 true LU77387A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1977-08-29

Family

ID=19826245

Family Applications (1)

Application Number Title Priority Date Filing Date
LU77387A LU77387A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1976-05-24 1977-05-23

Country Status (18)

Country Link
US (1) US4145434A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (2) JPS532465A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU509073B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE854915A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1122976A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (2) CH633536A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE2723209A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK157868C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (3) ES459024A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI65238C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2352800A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB1567862A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU173795B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE45419B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU77387A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL7605526A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SE (1) SE436202B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA772752B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0007450A1 (de) * 1978-07-07 1980-02-06 Ciba-Geigy Ag Azatetracyclische Carbonitrile, ihre Herstellung, pharmazeutische Präparate, die diese enthalten und deren Verwendung
EP0030916B1 (de) * 1979-12-10 1984-08-29 Ciba-Geigy Ag Azatetracyclische Carbonitrile
FR2504140A1 (fr) * 1981-04-16 1982-10-22 Centre Nat Rech Scient Nouveaux derives tetracycliques de la dibenzazepine, leur procede de preparation et les compositions pharmaceutiques en renfermant
DE3372369D1 (de) * 1982-05-18 1987-08-13 Hoffmann La Roche Pyrrole (3,4-d)(2)benzazepine derivatives
JPS62101941U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1985-12-16 1987-06-29
IE62754B1 (en) * 1988-08-26 1995-02-22 Akzo Nv Tetracyclic antidepressants
EP0569096A1 (en) * 1992-05-08 1993-11-10 Akzo Nobel N.V. Depot preparation
ES2193158T3 (es) * 1993-04-06 2003-11-01 Abbott Lab Compuestos tetraciclicos agonistas de la dopamina.
CZ284633B6 (cs) * 1994-03-02 1999-01-13 Akzo Nobel N. V. Farmaceutický prostředek a použití trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrolu pro výrobu farmaceutického prostředku
JP3274579B2 (ja) * 1995-01-12 2002-04-15 住友製薬株式会社 脳血管障害に伴う精神症候治療剤
CN1116291C (zh) * 1996-04-12 2003-07-30 詹森药业有限公司 取代的四环四氢呋喃衍生物
CN1257504A (zh) * 1997-05-26 2000-06-21 阿克佐诺贝尔公司 芳族磺酸盐
HRP20020305A8 (en) * 2002-04-10 2009-03-31 GlaxoSmithKline istra�iva�ki centar Zagreb d.o.o. 2-thia-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
HRP20020441A2 (en) * 2002-05-21 2003-12-31 Pliva D D 1-oxa-dibenzoazulen as inhibitor of production of tumor necrosis factors and intermediate for preparation thereof
HRP20030160A2 (en) * 2003-03-06 2005-04-30 Pliva-Istra�iva�ki institut d.o.o. 1-thiadibenzoazulene derivatives and biological action thereof
BRPI0410271A (pt) * 2003-05-16 2006-05-16 Pfizer Prod Inc combinações terapêuticas de antipsicóticos atìpicos com moduladores de gaba, anticonvulsivantes ou benzodiazepinas
HRP20030885A2 (en) * 2003-11-03 2005-08-31 Pliva-Istra�iva�ki institut d.o.o. USE OF 2-THIA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYYTEM DISEASES AND DISORDERS
HRP20030957A2 (en) * 2003-11-21 2005-08-31 Pliva-Istra�iva�ki institut d.o.o. USE OF 1-THIA-3-AZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
HRP20030959A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 2003-11-21 2005-10-31 Pliva-Istra�iva�ki institut d.o.o.
HRP20030958A2 (en) * 2003-11-21 2005-08-31 Pliva-Istra�iva�ki institut d.o.o. USE OF 1,3-DIAZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
HRP20030954A2 (en) * 2003-11-21 2005-08-31 Pliva D.D. USE OF 1-AZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
HRP20030953A2 (en) * 2003-11-21 2005-10-31 Pliva-Istra�iva�ki institut d.o.o. PREPARATION OF 1-AZA-2-OXA-DIBENZO[e,h]AZULENES AND THEIR USE FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
HRP20030956A2 (en) * 2003-11-21 2005-08-31 Pliva-Istra�iva�ki institut d.o.o. USE OF 1,2-DIAZA-DIBENZO[e,h]AZULENES FOR THE MANU
HRP20030955A2 (en) * 2003-11-21 2005-08-31 Pliva-Istra�iva�ki institut d.o.o. USE OF 1-OXADIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
HRP20040104A2 (en) * 2004-01-30 2005-10-31 Pliva-Istra�iva�ki institut d.o.o. Use of benzonaphthoazulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
BRPI0507609A (pt) * 2004-02-13 2007-07-03 Pfizer Prod Inc combinações terapêuticas de anti-psicóticos atìpicos com antagonistas de fator de liberação de corticotropina
JP2007537232A (ja) * 2004-05-11 2007-12-20 ファイザー・プロダクツ・インク 非定型抗精神病薬と５−ｈｔ１ｂ受容体拮抗薬の組合せ
EP1802301A1 (en) * 2004-10-15 2007-07-04 Pfizer Inc. Treatment of bipolar disorders and associated symptoms
SI1710241T1 (sl) * 2005-04-07 2010-02-26 Organon Nv Intermediatne spojine za pripravo trans-5-kloro-2-metil-2,3,3a, 12b-tetrahidro-1H-dibenz(2,3:6,7)oksepino(4,5-C)pirola
US7872147B2 (en) 2005-04-07 2011-01-18 N. V. Organon Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole
EP1917267B1 (en) * 2005-04-07 2008-12-24 N.V. Organon Crystal form of asenapine maleate
US7741358B2 (en) * 2005-04-14 2010-06-22 N.V. Organon Crystal form of asenapine maleate
WO2007046554A1 (ja) * 2005-10-21 2007-04-26 Sumitomo Chemical Company, Limited ジベンゾオキセピノピロール化合物の製造方法、その中間体及び該中間体の製造方法
TW200817414A (en) * 2006-07-05 2008-04-16 Organon Nv Process for the preparation of asenapine and intermediate products used in said process
US7750167B2 (en) * 2006-07-05 2010-07-06 N.V. Organon Process for the preparation of asenapine and intermediate products used in said process
WO2008040816A1 (en) * 2006-10-06 2008-04-10 N.V. Organon Amorphous asenapine and processes for preparing same
US7875729B2 (en) * 2007-01-05 2011-01-25 Synthon Bv Process for making asenapine
EP2170399A1 (en) * 2007-06-05 2010-04-07 Synthon B.V. Intranasal administration of asenapine and pharmaceutical compositions therefor
JP5245428B2 (ja) * 2007-07-06 2013-07-24 住友化学株式会社 トランス−ジベンゾオキセノピロール化合物の製造方法およびその中間体
ATE527266T1 (de) * 2008-01-04 2011-10-15 Organon Nv Herstellungsverfahren für asenapin und in diesem verfahren verwendete zwischenprodukte
WO2009104080A2 (en) 2008-02-20 2009-08-27 Targia Pharmaceuticals Cns pharmaceutical compositions and methods of use
EP2321011A1 (en) * 2008-06-25 2011-05-18 Pfizer Inc. Diaryl compounds and uses thereof
EP2453870A2 (en) * 2009-06-24 2012-05-23 MSD Oss B.V. Injectable formulations containing asenapine and method of treatment using same
AR077429A1 (es) 2009-07-29 2011-08-24 Organon Nv Compuestos hidroxiasenapina sus derivados y composiciones farmaceuticas que comprenden los mismos
CA2802990A1 (en) 2010-06-18 2011-12-22 Dr. Reddy's Laboratories Ltd. Asenapine maleate
US8653280B2 (en) 2010-07-29 2014-02-18 Laboratories Lesvi, S.L. Process for the preparation of asenapine
EP2640391B1 (en) 2010-11-15 2015-11-11 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
WO2012066565A2 (en) 2010-11-16 2012-05-24 Cadila Healthcare Limited Asenapine maleate amorphous and crystalline form and process for preparation thereof
EP2468750A1 (en) 2010-12-13 2012-06-27 Chemo Ibérica, S.A. Polymorphic forms of asenapine maleate and processes for their preparation
EP2468751B1 (en) 2010-12-24 2016-03-16 Medichem, S.A. Processes for the preparation of 5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole
WO2012123325A1 (en) 2011-03-11 2012-09-20 Medichem S.A. NEW CRYSTAL FORMS OF THE SALT OF TRANS-5-CHLORO-2-METHYL-2,3,3A,12b-TETRAHYDRO-1H-DIBENZO[2,3:6,7]OXEPINO[4,5-c]PYRROLE WITH MALEIC ACID
ITMI20110734A1 (it) 2011-05-02 2012-11-03 Olon Spa Sali cristallini di asenapina
EP2524921A1 (en) * 2011-05-17 2012-11-21 Sandoz AG Novel Crystalline Salts of Asenapine
EP2524919A1 (en) * 2011-05-17 2012-11-21 Sandoz AG Novel crystalline salts of Asenapine with organic Di-acids and Tri-acids
US9533994B2 (en) 2011-05-18 2017-01-03 Laboratorios Lesvi S.L. Monoclinic crystalline form of asenapine maleate with a specific particle size distribution
JP6014656B2 (ja) 2011-05-18 2016-10-25 ラビラトリオス レスビ エス エレ 化合物の多形体
WO2013024492A2 (en) 2011-07-01 2013-02-21 Megafine Pharma (P) Ltd. A process for the preparation of asenapine and novel salts thereof
US9145421B2 (en) 2011-07-20 2015-09-29 Ranbaxy Laboratories Limited Process for the preparation of asenapine maleate
WO2013035109A1 (en) 2011-09-08 2013-03-14 Mylan Laboratories Ltd Improved process for the preparation of asenapine maleate
EP2572703A1 (en) 2011-09-21 2013-03-27 Hexal AG Compressed oral dosage form for asenapine maleate
WO2013041604A1 (en) 2011-09-21 2013-03-28 Sandoz Ag Crystal form of asenapine maleate
AU2012346880A1 (en) 2011-11-28 2014-06-19 Sun Pharmaceutical Industries Limited Process for the preparation of asenapine intermediate
CN103254201B (zh) * 2012-02-21 2016-04-13 四川科伦药物研究有限公司 一种阿塞那平的制备方法
WO2013190481A1 (en) * 2012-06-21 2013-12-27 Alembic Pharmaceuticals Limited Process for preparing asenapine and salts of intermediates thereof
ITMI20121810A1 (it) 2012-10-24 2014-04-25 Chemo Iberica Sa Poliformi di maleato di asenapina e processo per la loro preparazione
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014127786A1 (en) 2013-02-22 2014-08-28 Zentiva, K.S. Orally disintegrating pharmaceutical composition comprising asenapine
CN103113379A (zh) * 2013-03-12 2013-05-22 盛世泰科生物医药技术(苏州)有限公司 阿塞那平马来酸盐的合成工艺
CN103351393B (zh) * 2013-07-03 2016-04-06 华裕(无锡)制药有限公司 用于制备阿森那平之还原剂及阿森那平之制备方法
CN112409363B (zh) 2013-12-20 2023-11-14 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂䓬衍生物、组合物和方法
CN103772400A (zh) * 2014-01-07 2014-05-07 万特制药(海南)有限公司 反式-5-氯-2,3,3a,12b-四氢-1H-二苯并[2,3:6,7]氧杂卓并[4,5-c]吡咯的制备方法
CN103772401A (zh) * 2014-01-07 2014-05-07 万特制药(海南)有限公司 11-氯-2,3,3a,12b-四氢-2-甲基-1H-二苯并[2,3:6,7]氧杂卓并[4,5-c]吡咯-1-酮的一种新精制方法
US11154510B2 (en) 2015-06-11 2021-10-26 Alrise Biosystems Gmbh Process for the preparation of drug loaded microparticles
JP6987384B2 (ja) 2015-06-19 2021-12-22 エージンバイオ， インコーポレイテッド ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
JP7149287B2 (ja) 2016-12-20 2022-10-06 エルテーエス ローマン テラピー－ジステーメ アーゲー アセナピンおよびポリシロキサンまたはポリイソブチレンを含有する経皮治療システム
CA3047451A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CA3067938A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
NZ772066A (en) 2018-06-19 2025-05-30 Agenebio Inc Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US12329862B2 (en) 2018-06-20 2025-06-17 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
ES3010131T3 (en) 2018-06-20 2025-04-01 Lts Lohmann Therapie Systeme Ag Transdermal therapeutic system containing asenapine
CN110183457A (zh) * 2019-06-27 2019-08-30 浙江天顺药业有限公司 一种阿塞那平及其制备方法
CN110606852B (zh) 2019-08-13 2021-02-05 浙江奥翔药业股份有限公司 制备阿塞那平的方法
US11679407B2 (en) * 2020-06-26 2023-06-20 Intel Corporation Liquid metal thermal interface material application
WO2023006954A1 (en) 2021-07-30 2023-02-02 Fundació Institut D'investigació Biomèdica De Bellvitge (Idibell) Asenapine for use in cancer
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH507232A (de) * 1968-11-27 1971-05-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen Thiepin- und Oxepinderivaten
NL178593C (nl) * 1974-01-31 1986-04-16 Akzo Nv Werkwijze ter bereiding van een farmaceutisch preparaat op basis van een tetracyclische verbinding en werkwijze voor de bereiding van de daarbij te gebruiken tetracyclische verbindingen.
AU469026B2 (en) * 1974-11-07 1976-01-29 Ciba-Geigy Ag New azepine derivatives and process forthe production thereof

Also Published As

Publication number Publication date
AU2533177A (en) 1978-11-23
SE7705957L (sv) 1977-11-25
HU173795B (hu) 1979-08-28
ES470407A1 (es) 1979-01-01
FI65238B (fi) 1983-12-30
DK157868B (da) 1990-02-26
BE854915A (fr) 1977-11-23
FI65238C (fi) 1984-04-10
GB1567862A (en) 1980-05-21
NL7605526A (nl) 1977-11-28
SE436202B (sv) 1984-11-19
JPS532465A (en) 1978-01-11
US4145434A (en) 1979-03-20
FR2352800B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1980-02-01
CH633536A5 (de) 1982-12-15
FI771635A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1977-11-25
DE2723209A1 (de) 1977-12-15
DK227477A (da) 1977-11-25
AU509073B2 (en) 1980-04-17
FR2352800A1 (fr) 1977-12-23
DK157868C (da) 1990-07-30
IE45419L (en) 1977-11-24
JPS61178965A (ja) 1986-08-11
IE45419B1 (en) 1982-08-25
ES459024A1 (es) 1978-11-01
CH637382A5 (de) 1983-07-29
JPS6134426B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1986-08-07
JPS6238348B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1987-08-17
DE2760372C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1991-05-29
ES470408A1 (es) 1979-01-01
ZA772752B (en) 1978-04-26
CA1122976A (en) 1982-05-04

Similar Documents

Publication Publication Date Title
FR2352800B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2345155B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR7700741A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK138287C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS52119292U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS5531955Y2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS5720468Y2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK140879C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS5638532B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS5650965Y2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR2352863B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS5364782U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS5370909U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS52138204U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS52155019U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS5331628U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS5321364U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CS192684B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JPS5315189U (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG26093A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH604049A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH614612A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DD123809A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU482216A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DD125378A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)